pharma news today obesity drugs glp-1 Dozens of new are coming: these are the ones to watch Pfizer moves forward with weight-loss

That said, Novo Nordisk and Eli Lilly aren't exactly sitting around doing nothing, so more GLP-1 developments are likely from this pair, as well

Primary Research To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships

For example, a months supply of generic Victoza [archived link] costs around $700 [archived link]

124 Therefore, it was speculated that peptide drugs are unlikely to be involved in the occurrence of transporter-mediated DDIs

The mechanisms of action of GLP-1RAs, SGLT2is, and nonsteroidal MRA are generally considered complementary and independent but may overlap in part, and the effects of each drug may not be completely additive when the three drugs are combined

Novo Nordisk's main competitor is Eli Lilly, which makes Zepbound and Mounjaro